GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Net Cash per Share

Akeso (HKSE:09926) Net Cash per Share : HK$1.67 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Akeso Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Akeso's Net Cash per Share for the quarter that ended in Dec. 2024 was HK$1.67.

The historical rank and industry rank for Akeso's Net Cash per Share or its related term are showing as below:

HKSE:09926' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 11.91   Med: 29.5   Max: 87.55
Current: 49.22

During the past 7 years, the highest Price-to-Net-Cash Ratio of Akeso was 87.55. The lowest was 11.91. And the median was 29.50.

HKSE:09926's Price-to-Net-Cash is ranked worse than
95.63% of 846 companies
in the Biotechnology industry
Industry Median: 3.505 vs HKSE:09926: 49.22

Akeso Net Cash per Share Historical Data

The historical data trend for Akeso's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Net Cash per Share Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
Get a 7-Day Free Trial 3.20 1.50 -0.76 0.53 1.67

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 1.26 0.53 -2.81 1.67

Competitive Comparison of Akeso's Net Cash per Share

For the Biotechnology subindustry, Akeso's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akeso's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Akeso's Price-to-Net-Cash falls into.


;
;

Akeso Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Akeso's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(7840.823-6407.624--64.572)/897.557
=1.67

Akeso's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as

Net Cash per Share (Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(7840.823-6407.624--64.572)/897.557
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akeso  (HKSE:09926) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Akeso Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Akeso's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Akeso Business Description

Traded in Other Exchanges
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in USA.
Executives
Xia Yu 2501 Other
Li Baiyong 2501 Other
Wang Zhongmin Maxwell 2501 Other
Green Court Capital Holdings Limited 2201 Interest of corporation controlled by you
Green Court Capital Management Limited 2102 Investment manager
Green Court Management Holdings Llc 2201 Interest of corporation controlled by you
Yao Yulin 2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Xia Yu 2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited 2301 Trustee
Aquae Hyperion Limited 2101 Beneficial owner
Htkf Investments Limited 2101 Beneficial owner

Akeso Headlines

No Headlines